

GAVI 5.0: PROGRESS, RISKS & CHALLENGES

BOARD MEETING

Anuradha Gupta, Deputy CEO

30 November - 2 December 2021, Virtual Meeting



Gavi 5.0 goals remain ambitious, seeking to leave no one behind



25%

Reduction in zero-dose children

300m

Children to be reached through routine immunisation

7-8m

Deaths averted

10%

Reduction in child mortality

**US\$
80-100b**

in economic benefits unlocked

The Alliance has recalibrated priorities in response to the pandemic

Leaving no one behind with immunisation

RECALIBRATED PRIORITIES

New

- Preventing **backsliding** and catching up on **missed children**
- Delivering **COVID-19 vaccines** to priority populations


Unchanged

- Reaching **zero-dose children** and missed communities
- Safeguarding **domestic financing**
- Ensuring **healthy markets** and preventing supply disruption

Rephased

- **Vaccine Investment Strategy (VIS)** deferred
- New **vaccine introductions** paced
- **Middle Income Countries (MICs)** approach rephased


Targeting zero-dose children would account for more than half of the incremental impact in Gavi 5.0



Deaths averted ignoring impact of maintaining coverage at 2020 levels

Less severe disruptions to routine immunisation in first half of 2021; but children still being missed

Number of children missing DTP3 versus 2019




- **Africa:** systems are still reaching the same number of children, but **not keeping pace with population growth** (>1.1m more children to be reached in 2021 than 2019)
- **Asia:** disruptions far greater with **backsliding in 2020**, but signs of recovery

Heightened risk of disruptions to routine immunisation as COVID-19 vaccines surge

- **COVID-19 vaccines see a massive surge** in the last quarter of 2021
- **~10 times more vaccination touchpoints** for COVID-19 vaccines, on top of routine immunisation, to achieve 70%
- **Impact on routine immunisation:**
 - EPI leadership overwhelmed
 - Health workforce diverted
 - RI syringes at risk of being cannibalised


Coverage of COVID-19 vaccination*



* As of 29 November 2021

Countries are facing fiscal challenges amid competing priorities

Countries fulfilling co-financing obligations ... but outlook for health financing seems bleak



- Co-financing obligations are **71% paid (US\$ 113m)**¹
- 2021: **6 waiver requests already received**
- 2020: **15 waivers requested; 9 approved**

- **13% increase in debt levels** in Gavi-57 countries
- **>70% funding** for COVID-19 response to come from domestic sources
- **~US\$5bn per year** additional investment needed in pandemic preparedness
- Government health spending in LICs is projected to **decrease; return to 2019 levels only by 2024**

¹As at end October

Integrated approach to RI and COVID-19 vaccination: the way forward

- Need for a **more joined-up view** of priorities at the Alliance level
- A **synergistic approach** to global forecasting, procurement and supply of vaccines, syringes and cold chain
- **Strong advocacy and clear guidance** to regions and countries to intertwine RI and COVID-19 vaccination
- Integration of **COVAX TA and PEF TCA**
- Rationalisation of COVAX **structures/ forums/ funding/ staffing related to supply and delivery**

'Whole Family' approach at Ogudu health centre, Nigeria, combining COVID-19 vaccination with healthcare services inc childhood vaccination, nutrition and screening for diseases



Questions for Board guidance

- Do the Alliance's **recalibrated priorities** require further adaptation at this point, acknowledging risks and challenges are constantly evolving?
- Is the proposal to adopt a **synergistic approach to COVID-19 vaccination and routine immunisation** the right direction to take? Are there any concrete suggestions that the Board might want to offer in this regard?
- Should the Alliance do anything else or different to **support countries to deliver on the core Gavi 5.0 priorities** including preventing backsliding of routine immunisation, and reaching zero-dose children?



THANK YOU